Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.
2.

Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Amass L, Kamien JB, Mikulich SK.

Drug Alcohol Depend. 2000 Feb 1;58(1-2):143-52.

PMID:
10669065
3.

Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.

Amass L, Bickel WK, Crean JP, Blake J, Higgins ST.

Psychopharmacology (Berl). 1998 Apr;136(3):217-25.

PMID:
9566806
4.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310
5.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
6.

A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.

Pérez de los Cobos J, Martin S, Etcheberrigaray A, Trujols J, Batlle F, Tejero A, Queraltó JM, Casas M.

Drug Alcohol Depend. 2000 Jun 1;59(3):223-33.

PMID:
10812283
7.

A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.

Bell J, Byron G, Gibson A, Morris A.

Drug Alcohol Rev. 2004 Sep;23(3):311-7.

PMID:
15370011
8.

Thrice-weekly versus daily buprenorphine maintenance.

Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR.

Biol Psychiatry. 2000 Jun 15;47(12):1072-9.

PMID:
10862807
9.

Alternate-day dosing during buprenorphine treatment of opioid dependence.

Amass L, Bickel WK, Higgins ST, Badger GJ.

Life Sci. 1994;54(17):1215-28.

PMID:
8164503
10.

Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.

Marsch LA, Bickel WK, Badger GJ, Jacobs EA.

Drug Alcohol Depend. 2005 Feb 14;77(2):195-204.

PMID:
15664721
11.
12.

A trial of integrated buprenorphine/naloxone and HIV clinical care.

Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S184-90.

PMID:
17109305
13.

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS.

N Engl J Med. 2006 Jul 27;355(4):365-74.

14.
15.

The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.

Winstock AR, Lea T, Ritter A.

Drug Alcohol Rev. 2007 Jul;26(4):411-6.

PMID:
17564877
16.

Buprenorphine: how to use it right.

Johnson RE, Strain EC, Amass L.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S59-77. Review.

PMID:
12738351
17.

Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.

Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE.

Drug Alcohol Depend. 1995 Nov;40(1):27-35.

PMID:
8746921
18.

Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.

Compton P, Ling W, Moody D, Chiang N.

Drug Alcohol Depend. 2006 Mar 15;82(1):25-31. Epub 2005 Sep 6.

PMID:
16144748
19.

Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

Chiang CN, Hawks RL.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S39-47. Review.

PMID:
12738349
20.

Supplemental Content

Support Center